Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mark Alan Goldberg Insider Profile
11 Followers
Mark Alan Goldberg, Director at ImmunoGen, holds 18.25K shares in Blueprint Medicines (Ticker: BPMC), holds 36.33K shares in GlycoMimetics (Ticker: GLYC), holds 0.00 shares in ImmunoGen (Ticker: IMGN).
Profitable Transactions
2 out of 5 Profitable Transactions
Average Return
+33.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Mark Alan Goldberg holds in companies
Most Profitable Insider Trade
Stock:
ImmunoGen
(IMGN)
(IMGN)
Rating:Informative Buy
Date:Dec 15, 2016 - Dec 15, 2017
Return:+280.40%
The most profitable trade made by Mark Alan Goldberg
Mark Alan Goldberg's Trading History
ImmunoGen
Feb 12, 2024
―
Uninformative Sell
―
$0.00
Audentes Therapeutics
Jan 15, 2020
―
Uninformative Sell
90.00K
$0.00
GlycoMimetics
Apr 02, 2024
Director
Uninformative Buy
13.75K
$8.46K
Aceragen
Apr 05, 2021
―
Uninformative Buy
13.87K
$18.47K
Blueprint Medicines
Jun 14, 2024
Director
Uninformative Buy
―
$1.65M
Synageva
Sep 19, 2014
―
Uninformative Sell
51.54K
―
List of latest transactions for each holding click on a transaction to see Mark Alan Goldberg's performance on stock
You May Also Like
Mark Alan Goldberg insider profile FAQ
What is the percentage of profitable transactions made by Mark Alan Goldberg?
The percentage of profitable transactions made by Mark Alan Goldberg is 40%.
What is the average return per transaction made by Mark Alan Goldberg?
The average return per transaction made by Mark Alan Goldberg is 33.60%.
What stocks does Mark Alan Goldberg hold?
Mark Alan Goldberg holds: IMGN, ~BOLD, GLYC, ACGN, BPMC, GEVA stocks.
What was Mark Alan Goldberg’s latest transaction?
Mark Alan Goldberg latest transaction was an Uninformative Buy of ―.
What was Mark Alan Goldberg's most profitable transaction?
Mark Alan Goldberg’s most profitable transaction was an Informative Buy of IMGN stock on December 15, 2016. The return on the trade was 280.40%.
What is Mark Alan Goldberg's role in ImmunoGen?
Mark Alan Goldberg's role in ImmunoGen is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.